Meshkat Shakila, F Duffy Sophie, K Tassone Vanessa, Lin Qiaowei, Ym Pang Hilary, Jung Hyejung, Lou Wendy, Bhat Venkat
Interventional Psychiatry Program, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
Department of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Transl Psychiatry. 2025 Feb 27;15(1):68. doi: 10.1038/s41398-025-03289-4.
Metabolic syndrome (MetS) is a condition that includes a cluster of risk factors for cardiovascular disease. In this paper, we aimed to evaluate the association between depressive symptoms, antidepressant use, duration of antidepressant use, antidepressant type and MetS. Data from the 2005-2018 National Health and Nutrition Examination Surveys were used in this study. Adults were included if they responded to the depressive symptoms and prescription medications questionnaires and had measures of blood pressure, waist circumference, triglycerides, high-density lipoprotein, and fasting plasma glucose. Participants were categorized by their antidepressant use (yes/no), type, and duration. This study included 14,875 participants (50.45% females), with 3616 (23.45%) meeting the criteria for MetS. Participants with higher depressive symptom scores (aOR = 1.04, 95% CI: 1.02, 1.05, p < 0.001) or those with depressive symptoms (aOR = 1.42, 95% CI: 1.17, 1.73, p = 0.001) had higher odds of MetS. A similar associations was seen among those who were on antidepressants compared to those who were not on antidepressants (aOR = 1.24, 95% CI: 1.03, 1.50, p = 0.025). Duration of antidepressant use was not significantly associated with MetS. Participants on tricyclic antidepressants had greater odds of MetS compared to those not taking any antidepressants (aOR = 2.27, 95% CI: 1.31, 3.93, p = 0.004). Our study provides evidence of the association between depressive symptoms, antidepressant use, and MetS, highlighting the importance of monitoring metabolic and cardiovascular alterations in individuals of depression.
代谢综合征（MetS）是一种包含一系列心血管疾病风险因素的病症。在本文中，我们旨在评估抑郁症状、抗抑郁药使用情况、抗抑郁药使用时长、抗抑郁药类型与代谢综合征之间的关联。本研究使用了2005年至2018年国家健康与营养检查调查的数据。纳入的成年人需对抑郁症状和处方药问卷作出回应，并测量血压、腰围、甘油三酯、高密度脂蛋白和空腹血糖。参与者按抗抑郁药使用情况（是/否）、类型和使用时长进行分类。本研究纳入了14875名参与者（50.45%为女性），其中3616人（23.45%）符合代谢综合征的标准。抑郁症状评分较高的参与者（调整优势比[aOR]=1.04，95%置信区间[CI]：1.02，1.05，p<0.001）或有抑郁症状的参与者（aOR=1.42，95%CI：1.17，1.73，p=0.001）患代谢综合征的几率更高。与未服用抗抑郁药的人相比，服用抗抑郁药的人也有类似的关联（aOR=1.24，95%CI：1.03，1.50，p=0.025）。抗抑郁药的使用时长与代谢综合征无显著关联。与未服用任何抗抑郁药的人相比，服用三环类抗抑郁药的参与者患代谢综合征的几率更高（aOR=2.27，95%CI：1.31，3.93，p=0.004）。我们的研究提供了抑郁症状、抗抑郁药使用与代谢综合征之间存在关联的证据，强调了监测抑郁症患者代谢和心血管变化的重要性。
